Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt)
|ClinicalTrials.gov Identifier: NCT01904903|
Recruitment Status : Completed
First Posted : July 22, 2013
Last Update Posted : June 18, 2020
HER2 positive breast cancer cells have more HER2 receptor (a protein on the surface of cells) than normal breast cells. Approximately 30% of patients with breast cancer have HER2 positive breast cancer. Before HER2 targeted therapies (i.e. treatments that directly block the receptor HER2) were developed, patients with HER2 positive breast cancer had a very aggressive form of disease. With the use of trastuzumab, an anticancer drug that directly targets the receptor HER2, and more recently, pertuzumab and ado-trastuzumab emtansine, patients are able to live longer and have better control of their cancer.
Unfortunately the use of HER2 targeted therapies can increase the risk of heart problems and for this reason these treatments were only studied and approved for patients with normal heart function.
In this study we plan to give HER2 targeted therapies to patients with HER2 positive breast cancer and mildly decreased heart function along with concomitant evaluation by a heart doctor (called cardiologist) and appropriate medications to strengthen the heart. We will do frequent monitoring of the heart function with a test called echocardiogram that will give us a detailed "picture" of the heart. We will also draw blood along with routine blood tests to try to understand why some patients develop heart problems and others do not. The study will take a maximum of 12 months and patients will be monitored for 6 additional months.
We hypothesize that it is safe to administer HER2 targeted therapies to patients with breast cancer and mildly decreased heart function, i.e. LVEF between 40 and 50%, while on appropriate heart medications.
|Condition or disease||Intervention/treatment||Phase|
|HER2 Positive Breast Cancer Left Ventricular Function Systolic Dysfunction||Drug: Trastuzumab Drug: Pertuzumab Drug: Ado Trastuzumab Emtansine||Phase 2|
Title: A pilot study evaluating the cardiac safety of HER2 targeted therapy (non-lapatinib) in patients with HER2 positive breast cancer and reduced left ventricular function Phase: Pilot study Study Duration: 4 years with up to 5 additional years of follow up Study Center(s): 3 centers will be participating: MedStar Washington Hospital Center (MWHC), MedStar Georgetown University Hospital (MGUH) and Memorial Sloan Kettering Cancer Center (MSKCC) Primary Objective: To evaluate the cardiac safety of HER2 targeted therapy (non-lapatinib) in patients with HER2 positive breast cancer and reduced left ventricular ejection fraction (LVEF) when given concomitantly with cardiac treatment.
- To evaluate time to development of cardiac event or asymptomatic worsening of cardiac function
- Absolute changes in LVEF
- Delays in HER2 therapy attributed to cardiac causes
- Correlations between echocardiographic myocardial strain
- cTnI and hs-cTnT at baseline and over time with cardiac events and asymptomatic worsening of cardiac function Sample size: 30 patients
Diagnosis and Main Inclusion Criteria:
- HER2 positive breast cancer, stage I-IV.
- Mildly decreased cardiac function (LVEF between 40 and 49%) prior to or while receiving non-lapatinib HER2 targeted therapy
- Beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses
Oncology study Products, Doses, Routes, Regimens:
- Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.
- Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.
- Ado-trastuzumab emtansine: 3.6mg/kg IV every three weeks. Note: both trastuzumab and pertuzumab may be administered alone or in combination with other systemic or radiation therapy.
Duration of drug administration: Maximum of 12 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function|
|Actual Study Start Date :||October 2013|
|Actual Primary Completion Date :||June 2019|
|Actual Study Completion Date :||June 2020|
HER2 therapies, cardiac medications
Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses
Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:
Other Name: Herceptin
Other Name: Perjeta
Drug: Ado Trastuzumab Emtansine
Other Name: Kadcyla
- Proportion of patients who complete planned oncologic therapy without the development of a cardiac event or asymptomatic worsening of cardiac function. [ Time Frame: Up to 18 months. ]
Cardiac events are defined as any of the following:
- Presence of symptoms attributable to heart failure as confirmed by a cardiologist
- Cardiac arrhythmia requiring pharmacological or electrical treatment
- Myocardial infarction
- Sudden cardiac death or death due to myocardial infarct, arrhythmia or heart failure
Asymptomatic worsening of cardiac function defined as:
- Asymptomatic decline in LVEF > 10% points from baseline and/or EF < 35% corroborated by a confirmatory echocardiogram in 2-4 weeks
Planned oncologic therapy is defined as:
- In the adjuvant setting: completion of 1 year total of HER2 targeted therapy. If a patient already received part of the planned HER2 targeted therapy prior to enrollment in this trial, planned oncologic therapy will be achieved when a total of 1 year is completed.
- In the metastatic setting: cessation of treating regimen due to progressive disease or non-cardiac toxicity or non-cardiac death.
- Median time to development of an event defined as cardiac event or asymptomatic worsening of left ventricular dysfunction, among patients who developed one event. [ Time Frame: Up to 18 months. ]Descriptive exploratory analysis
- Absolute changes in LVEF during HER2 targeted therapy [ Time Frame: Up to 18 months. ]Descriptive exploratory analysis
- HER2 therapy holds attributed to proportion of patients with symptomatic or asymptomatic cardiotoxicity. [ Time Frame: Up to 12 months. ]Hold is defined as any delay or discontinuation of HER2 targeted therapy due to cardiac toxicity. One cycle of HER2 targeted therapy will be considered 3 weeks. One therapy hold will be defined as any 3-week HER2 targeted therapy missed dose or 1/3 if one weekly trastuzumab dose. For patients who had a hold and resumed HER2 targeted therapy, duration of treatment hold will be described.
- Correlation of global longitudinal myocardial strain with cardiac events and asymptomatic worsening of cardiac function [ Time Frame: Up to 18 months. ]Descriptive exploratory analysis
- Correlation of standard cardiac troponin I and highly sensitive cardiac troponin T with cardiac events and asymptomatic worsening of cardiac function [ Time Frame: Up to 18 months. ]Descriptive exploratory analysis
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01904903
|United States, District of Columbia|
|Washington Cancer Institute at MedStar Washington Hospital Center|
|Washington, District of Columbia, United States, 20010|
|MedStar Georgetown University Hospital|
|Washington, District of Columbia, United States, 20057|
|Principal Investigator:||Sandra M Swain, MD||Washington Cancer Institute at MedStar Washington Hospital Center|